CRX-648 | 99011-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: CRX-648
• 英文别名: 1-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-4-amine；2-(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)ethanol；2-(4-aminoimidazo[4,5-c]quinolin-1-yl)ethanol
• CAS: 99011-22-0
• 化学式: C₁₂H₁₂N₄O
• 分子量: 228.253
• InChiKey: OWKZMVASJFEUKK-UHFFFAOYSA-N

物化性质

• 熔点：
  260-262 °C(Solv: N,N-dimethylformamide (68-12-2))
• 沸点：
  527.2±60.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  CRX-648 在 氯化亚砜 作用下， 反应 2.0h， 生成 1-(2-chloroethyl)-1H-imidazo[4,5-c]quinolin-4-amine
  参考文献：
  名称：

  Thioether substituted imidazoquinolines

  摘要：

  咪唑喹啉和四氢咪唑喹啉化合物，在1位含有硫醚功能团，可用作免疫反应调节剂。本发明的化合物和组合物能够诱导多种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的多种疾病。

  公开号：

  US06667312B2
• 作为产物：
  描述：

  4-chloro-1-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinoline 在 氨 作用下， 以 甲醇 为溶剂， 生成 CRX-648
  参考文献：
  名称：

  1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use

  摘要：

  1H-咪唑并[4,5-c]喹啉-4-胺是抗病毒药物。还描述了使用这些化合物的药理学方法以及含有这些化合物的药物组合物。

  公开号：

  US04689338A1

文献信息

• Aryl ether substituted imidazoquinolines
  申请人：——

  公开号：US20030212092A1

  公开（公告）日：2003-11-13

  Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

  咪唑喹啉和四氢咪唑喹啉化合物，在1位点含有醚和芳基或烯基功能团，可用作免疫应答调节剂。该发明的化合物和组合物可以诱导各种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的各种疾病。
• 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
  申请人：Riker Laboratories, Inc.

  公开号：US04689338A1

  公开（公告）日：1987-08-25

  1H-Imidazo[4,5-c]quinolin-4-amines which are antivirals. Pharmacological methods of using such compounds and pharmaceutical compositions containing such compounds are also described.

  1H-咪唑并[4,5-c]喹啉-4-胺是抗病毒药物。还描述了使用这些化合物的药理学方法以及含有这些化合物的药物组合物。
• HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS
  申请人：YU Chongxi

  公开号：US20100021394A1

  公开（公告）日：2010-01-28

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了一种新型高穿透力化合物（HPC）或高穿透力前药（HPP）的组合物，其中包括1H-咪唑[4,5-c]喹啉-4-胺和1H-咪唑[4,5-c]喹啉-4-胺相关化合物。这些化合物能够高效地穿过生物屏障。HPP可以在穿过生物屏障后被转化为原始活性药物或药物代谢物，从而可以治疗与原始药物或代谢物相关的疾病。此外，HPP能够到达原始药物无法接触到或无法在目标区域产生足够浓度的区域，从而提供新型治疗方法。HPP可以通过各种给药途径给予受试者，例如在治疗区域局部给药以高浓度作用或系统性给药给生物受试者，并以更快的速度进入全身循环。
• HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF
  申请人：YU Chongxi

  公开号：US20130131100A1

  公开（公告）日：2013-05-23

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了1H-咪唑[4,5-c]喹啉-4-胺和1H-咪唑[4,5-c]喹啉-4-胺相关化合物的新型高渗透性组合物（HPC）或高渗透性前药（HPP），能够以高渗透效率穿过生物屏障。HPP能够在穿过生物屏障后转化为母药或药物代谢物，从而可以治疗母药或代谢物所能治疗的病症。此外，HPP能够到达母药可能无法进入或在目标区域提供足够浓度的区域，从而提供新型治疗方法。HPP可以通过各种给药途径给予受试者，例如，局部给药于具有高浓度的病症作用部位或系统性给药于生物体中并以更快的速率进入全身循环。
• 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
  申请人：RIKER LABORATORIES, INC.

  公开号：EP0145340B1

  公开（公告）日：1990-01-24